Fed. Circ. Backs USPTO's Term Adjustment For Drug Patent
The Federal Circuit said Tuesday that Actelion Pharmaceuticals Ltd. was not entitled to a patent term adjustment that would have added several days to the life of a patent beyond an...To view the full article, register now.
Already a subscriber? Click here to view full article